RxDoctor Payments Data

Wilmer Columbie Sardinas, MD

General Practice · Orlando, FLNPI 1699205310

Payments from drug & device makers

$619in general payments, 2019–2025

Across 26 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Watermark Medical, Inc.$193
  • AstraZeneca$154
  • GSK$51
  • Renalytix AI, Inc.$44
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$39
  • Phadia US Inc.$33
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$619 in reported general payments places this provider in the 70th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$2,242
Medicare patients
14
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin190$265,693
OzempicSemaglutide124$175,926
EliquisApixaban112$137,313
TrulicityDulaglutide76$107,143
TradjentaLinagliptin49$63,421
MounjaroTirzepatide48$51,742
FarxigaDapagliflozin Propanediol35$46,680
JanuviaSitagliptin Phosphate30$43,729
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$42,351
LinzessLinaclotide39$32,527
EntrestoSacubitril/Valsartan26$27,818
XareltoRivaroxaban12$19,177
Tresiba Flextouch U-100Insulin Degludec24$18,614
JanumetSitagliptin Phos/Metformin Hcl17$18,409
Breo ElliptaFluticasone/Vilanterol46$16,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$16$336,949254 claims
Novo NordiskOzempic, Novolog$33$180,586138 claims
Lilly USA, LLCTrulicity, Mounjaro$26$158,885124 claims
PfizerEliquis$18$137,313112 claims
AstraZenecaFarxiga, Brilinta, Symbicort$154$69,45079 claims
GSKTrelegy Ellipta, Breo Ellipta$51$58,71887 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,901 general practice providers in Florida.

Other general practice in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →